We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Hypothermic Versus Normothermic Ex-vivo Preservation. (DCDNet)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04744389
Recruitment Status : Recruiting
First Posted : February 9, 2021
Last Update Posted : July 26, 2022
Sponsor:
Collaborators:
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Information provided by (Responsible Party):
Davide Ghinolfi, Azienda Ospedaliero, Universitaria Pisana

Brief Summary:

Study groups:

The study is a multicenter (Pisa and Milan), prospective, randomized study comparing D-HOPE (HMP) vs NMP in DCD and ECD-DBD (extended criteria brain-dead donors). Once a DCD or a DBD with extended criteria (ECD-DBD) meets the inclusion criteria, they are randomized as follow:

  1. 20 liver grafts from DCD after normothermic regional perfusion (NRP) matching the inclusion criteria are randomized 1:1 to hypothermic machine perfusion (HMP) vs normothermic machine perfusion (NMP) and then transplanted.
  2. 40 liver grafts from ECD-DBD matching the inclusion criteria are randomized 1:1 to hypothermic machine perfusion (HMP) vs normothermic machine perfusion (NMP) and then transplanted

Condition or disease Intervention/treatment Phase
End Stage Liver DIsease Device: Hypothermic Machine Perfusion Device: Normothermic Machine Perfusion Not Applicable

Detailed Description:

The persistent mismatch between patients waiting for a liver transplant (LT) and grafts availability promoted the use of donation after circulatory death (DCD). Italian law requires 20 minutes of continous flatline electrocardiogram to declared individual's circulatory death and such a long period of warm ischemia time forced the development of protocols using abdominal normothermic regional perfusion (NRP) followed by ex-vivo graft reperfusion by means of machine perfusion technology (MP) for its potential to minimize ischemia/reperfusion damage and promote organ repair and reconditioning prior to transplantation. An extensive evaluation of all DCD donors might increase donation rate by 30%, but, while kidney transplant from DCD donors is well implemented, no definitive data exist on the optimal use of NRP and MP in liver and pancreas transplantation and an organizational model is far to be implemented. Moreover, a randomized trial comparing hypothermic vs normothermic ex-vivo perfusion has never been performed. The proposed project will perform a pilot, open, randomized, prospective trials to evaluate the sequential use of NRP followed by ex-vivo MP (hypothermic (HMP) vs normothermic (NMP)) by measuring several indicators of organ damage and recovery with the target to set up the optimal organizational model for DCD donation:

  1. Twenty LT from DCD donors after NRP (considered transplantable for the acceptance criteria in use) will be randomized 1:1 to ex-vivo HMP or NMP (multicenter study together with the center in Milan)
  2. 40 liver grafts from ECD-DBD matching the inclusion criteria are randomized 1:1 to hypothermic machine perfusion (HMP) vs normothermic machine perfusion (NMP) and then transplanted To assess organ damage and repair capacity, the following investigations will be performed: -biomarkers of apoptosis, necrosis, innate-mediated inflammation and its resolution, angiogenesis and thrombosis during NRP -circulating biomarkers indicating damage, proliferation, angiogenetic and tissue remodelling factors; a targeted-metabolomic and lipidomic profiling during ex-vivo HMP or NMP in the perfusate and on blood samples in the peri and post-operative period; bile composition on graft subjected to NMP. Evaluation of necrosis, apoptosis and proliferation, immunohistochemical analysis, a targeted-metabolomic and lipidomic profiling, ATP measurement, and electronic microscopy investigations will be performed on liver tissue and bile duct biopsies after NRP, before and after ex-vivo reperfusion, and immediately after reperfusion in the recipient (only for transplantable grafts) Based on the collected data a new algorithm of organ evaluation, procurement, preservation and reconditioning will be formulated and disseminated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Optimization of an Evidence-based Organizational Model of Liver and Pancreas Transplant Using Cardiac Death Donors: a Pilot, Prospective, Randomized, Multicenter Study for the Comparison of Hypothermic Versus Normothermic Ex-vivo Preservation.
Actual Study Start Date : December 15, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : March 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypothermia

Arm Intervention/treatment
Experimental: Hypothermic Machine Perfusion
uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
Device: Hypothermic Machine Perfusion
The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
Other Name: Hypothermic machine perfusion (HMP)

Experimental: Normothermic Machine Perfusion
uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
Device: Normothermic Machine Perfusion
Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
Other Name: Normothermic machine perfusion (NMP)




Primary Outcome Measures :
  1. Rate of graft loss [ Time Frame: at 6 months postoperatively ]
    Death of patient, relisting or Retransplantation. Composite Outcome

  2. Rate of Ischemic Type Biliary Lesions (ITBL) [ Time Frame: at 6 months postoperatively ]
    ITBL as assessed by MRI / MRCP. Composite Outcome


Secondary Outcome Measures :
  1. 1-year graft survival [ Time Frame: 1-year postoperatively ]
  2. 1-year patients survival [ Time Frame: 1-year postoperatively ]
  3. level of BCL-2/BAX at the liver histology [ Time Frame: after 2 hours of perfusion ]
    BCL-2/BAX is members of the Bcl-2 family of regulator proteins that regulate cell death and correlates with graft loss

  4. level of Soluble Keratin 18 in the perfusate [ Time Frame: after 2 hours of perfusion ]
    Soluble Keratin 18 is a marker of necrosis and apoptosis and correlates with graft loss

  5. level of HMGB1in the perfusate [ Time Frame: after 2 hours of perfusion ]
    HMGB1 Acts as danger associated molecular pattern (DAMP) molecule that amplifies immune responses during tissue injury and correlates with graft loss



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

GRAFT:

Inclusion criteria:

DCD:

  • no absolute contraindications as per Italian National Transplant center (CNT)
  • donor age ≤70 years
  • witnessed and documented cardiac arrest
  • macro-vescicular steatosis <30% at liver biopsy
  • necrosis <5% at liver biopsy
  • fibrosis <2 as per Ishak's score at liver biopsy
  • arteriolar thickening <60% at liver biopsy
  • WIT ≤160 minutes
  • ALT <1000 UI/L during NRP
  • downward trend lactate during NRP

DBD:

  • no absolute contraindications as per Italian National Transplant center (CNT)
  • donor age > 70 years
  • macro-steatosis between 30 and 50% at liver biopsy

Exclusion criteria:

DCD:

  • absolute contraindications as per Italian National Transplant center (CNT)
  • donor age >70 years
  • macro-vescicular steatosis >30% at liver biopsy
  • necrosis >5% at liver biopsy
  • fibrosis >2 as per Ishak's score at liver biopsy
  • severe macroangiopathy (arteriolar thickening >60% at liver biopsy)
  • WIT >160 minutes
  • ALT >1000 UI/L during NRP
  • uptrend lactate during NRP

DBD:

  • absolute contraindications as per Italian National Transplant center (CNT)
  • donor age < 70 years
  • macro-steatosis between > 50% at liver biopsy

RECIPIENTS

Inclusion criteria:

  • Subject must be greater than or equal to 18 years of age.
  • Subject with end-stage liver disease who is actively listed for primary liver transplantation
  • Subject, or a legally authorized representative, has given informed consent to participate in the study

Exclusion criteria:

  • Subject is currently listed as a UNOS status 1A.
  • Subject is requiring oxygen therapy via ventilator/respiratory support.
  • Subject is planned to undergo simultaneous solid organ transplant.
  • Subject is pregnant at the time of transplant.
  • Subject MELD score 25 or higher
  • Subject receives re-transplantation of liver.
  • Any medical conditions contro-indicating the use of DCD grafts at transplant surgeon/hepatologist evaluation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04744389


Contacts
Layout table for location contacts
Contact: Davide Ghinolfi, MD, PhD 00393282185278 d.ghinolfi@ao-pisa.toscana.it

Locations
Layout table for location information
Italy
UO Chirurgia Epatica e del Trapianto di Fegato Recruiting
Pisa, Italy, 56124
Contact: Davide Ghinolfi, MD    +39050995421    d.ghinolfi@ao-pisa.toscana.it   
Sub-Investigator: Fabio Melandro, MD, PhD         
Sponsors and Collaborators
Azienda Ospedaliero, Universitaria Pisana
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Publications:
Layout table for additonal information
Responsible Party: Davide Ghinolfi, Principal Investigator, Azienda Ospedaliero, Universitaria Pisana
ClinicalTrials.gov Identifier: NCT04744389    
Other Study ID Numbers: D52F20000740002
First Posted: February 9, 2021    Key Record Dates
Last Update Posted: July 26, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Davide Ghinolfi, Azienda Ospedaliero, Universitaria Pisana:
ex-situ perfusion
organ preservation
normothermic perfusion
hypothermic perfusion
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
End Stage Liver Disease
Hypothermia
Digestive System Diseases
Liver Failure
Hepatic Insufficiency
Body Temperature Changes